

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Little Green Pharma Ltd
ACN 615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Long
Date of last notice	4 March 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Paul Frederick Long <The Long A/C> Mr Long is a beneficiary
Date of change	1 September 2025

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	Direct 499,769 ordinary shares Paul Frederick Long <The Long A/C> 1,926,191 ordinary shares 500,000 ordinary shares (escrowed until 31 March 2026) 2,000,000 options exercisable at \$0.138 expiring 31 Jul 2027 500,000 performance rights class F expiring 17 Aug 2026 500,000 performance rights class G expiring 17 Aug 2026 500,000 performance rights class H expiring 17 Aug 2026 500,000 performance rights class I expiring 17 Aug 2026 500,000 performance rights class J expiring 17 Aug 2026 500,000 performance rights class K expiring 17 Aug 2026 1,000,000 retention share rights vesting 21 Mar 2026
Class	Options exercisable at \$0.1725 expiring 31 Jul 2028
Number acquired	2,000,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil. Options acquired under the Company's Long Term Incentive Plan and approved by shareholders on 21 Aug 2025

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	Direct 499,769 ordinary shares Paul Frederick Long <The Long A/C> 1,926,191 ordinary shares 500,000 ordinary shares (escrowed until 31 March 2026) 2,000,000 options exercisable at \$0.138 expiring 31 Jul 2027 2,000,000 options exercisable at \$0.1725 expiring 31 Jul 2028 500,000 performance rights class F expiring 17 Aug 2026 500,000 performance rights class G expiring 17 Aug 2026 500,000 performance rights class H expiring 17 Aug 2026 500,000 performance rights class I expiring 17 Aug 2026 500,000 performance rights class J expiring 17 Aug 2026 500,000 performance rights class K expiring 17 Aug 2026 1,000,000 retention share rights vesting 21 Mar 2026
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options acquired under the Company's Long Term Incentive Plan and approved by shareholders on 21 Aug 2025

Appendix 3Y

Change of Director's Interest Notice

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Angus McDougall Caithness
Date of last notice	6 September 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Banquo Consulting Pty Ltd Mr Caithness is a director Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund Mr Caithness is a director of the trustee and beneficiary
Date of change	1 September 2025

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p><u>Direct</u> 5,751,441 Ordinary shares 1,000,000 Retention Share Rights 2,000,000 Unlisted Options, exercisable at \$0.138 each, expiring 31 July 2027</p> <p><u>Indirect</u> Banquo Consulting Pty Ltd 5,413,333 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights</p> <p>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund 316,667 Ordinary shares</p>
Class	Unlisted Options exercisable at \$0.1725 expiring 31 Jul 2028
Number acquired	2,000,000 Unlisted Options, exercisable at \$0.1725 each, expiring 31 July 2028
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil. Options acquired under the Company's Long Term Incentive Plan and approved by shareholders on 21 Aug 2025

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	<p><u>Direct</u> 5,751,441 Ordinary shares 1,000,000 Retention Share Rights 2,000,000 Unlisted Options, exercisable at \$0.138 each, expiring 31 July 2027 2,000,000 Unlisted Options, exercisable at \$0.1725 each, expiring 31 July 2028</p> <p><u>Indirect</u> Banquo Consulting Pty Ltd 5,413,333 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights</p> <p>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund 316,667 Ordinary shares</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options acquired under the Company's Long Term Incentive Plan and approved by shareholders on 21 Aug 2025

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Fleta Jennifer Solomon
Date of last notice	6 September 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Fleta Solomon Super Pty Ltd as trustee for Solomon Super Fund Ms Solomon is a director of the trustee and beneficiary
Date of change	1 September 2025
No. of securities held prior to change * opening balance from previous interest notice reduced by 36,000 for conversion of share rights on 24 April 2023	Direct 20,723,216 fully paid ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 1,000,000 Retention Rights 1,200,000 Unlisted Options, exercisable at \$0.138 each, expiring 31 July 2027 Fleta Solomon Super Pty Ltd as trustee for Solomon Super Fund 1,150,000 fully paid ordinary shares
Class	Unlisted Options, exercisable at \$0.1725 each, expiring 31 July 2028

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	2,000,000 Unlisted Options, exercisable at \$0.1725 each, expiring 31 July 2028
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil. Options acquired under the Company's Long Term Incentive Plan and approved by shareholders on 21 Aug 2025
No. of securities held after change	<p><u>Direct</u></p> <p>20,723,216 fully paid ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 1,000,000 Retention Rights 1,200,000 Unlisted Options, exercisable at \$0.138 each, expiring 31 July 2027 1,200,000 Unlisted Options, exercisable at \$0.1725 each, expiring 31 July 2028</p> <p><u>Fleta Solomon Super Pty Ltd as trustee for Solomon Super Fund</u> 1,150,000 fully paid ordinary shares</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Options acquired under the Company's Long Term Incentive Plan and approved by shareholders on 21 Aug 2025

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.